DK3463457T3 - Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom - Google Patents

Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom Download PDF

Info

Publication number
DK3463457T3
DK3463457T3 DK17730627.1T DK17730627T DK3463457T3 DK 3463457 T3 DK3463457 T3 DK 3463457T3 DK 17730627 T DK17730627 T DK 17730627T DK 3463457 T3 DK3463457 T3 DK 3463457T3
Authority
DK
Denmark
Prior art keywords
nivolumab
blockade
lymphoma
refractory hodgkin
hodgkin
Prior art date
Application number
DK17730627.1T
Other languages
Danish (da)
English (en)
Inventor
Benedetto Farsaci
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3463457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3463457T3 publication Critical patent/DK3463457T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17730627.1T 2016-06-02 2017-06-01 Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom DK3463457T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344880P 2016-06-02 2016-06-02
PCT/US2017/035492 WO2017210453A1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Publications (1)

Publication Number Publication Date
DK3463457T3 true DK3463457T3 (da) 2023-10-02

Family

ID=59067911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17730627.1T DK3463457T3 (da) 2016-06-02 2017-06-01 Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom

Country Status (17)

Country Link
US (3) US11083790B2 (OSRAM)
EP (2) EP4248990A3 (OSRAM)
JP (3) JP7175198B2 (OSRAM)
KR (2) KR20190015377A (OSRAM)
CN (1) CN109475633A (OSRAM)
DK (1) DK3463457T3 (OSRAM)
ES (1) ES2954139T3 (OSRAM)
FI (1) FI3463457T3 (OSRAM)
HR (1) HRP20230864T1 (OSRAM)
HU (1) HUE062398T2 (OSRAM)
LT (1) LT3463457T (OSRAM)
PL (1) PL3463457T3 (OSRAM)
PT (1) PT3463457T (OSRAM)
RS (1) RS64388B1 (OSRAM)
SI (1) SI3463457T1 (OSRAM)
SM (1) SMT202300290T1 (OSRAM)
WO (1) WO2017210453A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
HUE063911T2 (hu) 2016-06-02 2024-02-28 Bristol Myers Squibb Co Anti-PD-1 antitest felhasználása anti-CD30 atnitesttel kombinációban limfóma kezelésben
DK3463457T3 (da) 2016-06-02 2023-10-02 Bristol Myers Squibb Co Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
JP2022527177A (ja) * 2019-03-28 2022-05-31 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20060032289A1 (en) 2004-08-11 2006-02-16 Pinnaduwage Lal A Non-optical explosive sensor based on two-track piezoresistive microcantilever
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
DK3463457T3 (da) 2016-06-02 2023-10-02 Bristol Myers Squibb Co Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom

Also Published As

Publication number Publication date
KR20190015377A (ko) 2019-02-13
EP3463457B1 (en) 2023-06-28
EP4248990A3 (en) 2024-01-03
SI3463457T1 (sl) 2023-09-29
JP7568698B2 (ja) 2024-10-16
PL3463457T3 (pl) 2023-08-21
JP7175198B2 (ja) 2022-11-18
HRP20230864T1 (hr) 2023-11-10
EP3463457A1 (en) 2019-04-10
WO2017210453A1 (en) 2017-12-07
EP4248990A2 (en) 2023-09-27
ES2954139T3 (es) 2023-11-20
PT3463457T (pt) 2023-09-07
JP2019517504A (ja) 2019-06-24
US20250134996A1 (en) 2025-05-01
JP2025020119A (ja) 2025-02-12
US11083790B2 (en) 2021-08-10
LT3463457T (lt) 2023-09-11
US20190290757A1 (en) 2019-09-26
SMT202300290T1 (it) 2023-11-13
KR20230038318A (ko) 2023-03-17
JP2023025012A (ja) 2023-02-21
US20220025049A1 (en) 2022-01-27
FI3463457T3 (fi) 2023-09-12
RS64388B1 (sr) 2023-08-31
CN109475633A (zh) 2019-03-15
HUE062398T2 (hu) 2023-10-28

Similar Documents

Publication Publication Date Title
DK3463457T3 (da) Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom
EP2961844A4 (en) MANIPULATED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIO-CATALYSIS
EP3259734A4 (en) REDUCTION OF APERTURE
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
EP2973806A4 (en) PROTECTION STRUCTURES FOR ELECTRODES
DK2947246T3 (da) Snap-in-hængsel med dæmpet lukning
BR112016026251A2 (pt) processo de polimerização em lama para formar polietileno
FR3052789B1 (fr) Composition d&#39;acier
EP3369837A4 (en) PLATED STEEL PLATE
EP3319643A4 (en) HBED-BISPHOSPHONATE, RADIOMETALL CONJUGATE THEREOF AND THEIR USE AS THERANOSTIC AGENTS
MA40911A (fr) Compositions de piégeage d&#39;oxygène ne nécessitant pas de période d&#39;induction
GB2550703B (en) Crosslinked polymer compositions with two crosslinkers for use in subterranean formation operations
DK3371126T3 (da) Manipuleret hybrid cementbaseret sammensætning med øget modstandsdygtighed over for befugtning
EP2969006A4 (en) COMPOSITIONS AND METHOD FOR TREATING IMMUNE WEAKAGE VIRUS INFECTION
LT3419598T (lt) Fosfomicino kompozicija, skirta parenteraliniam įvedimui
EP3222660C0 (en) SBR COMPOSITION OF A TORSIONAL DAMPER AND TORSIONAL DAMPER
DK3236811T3 (da) Beskyttelsesartikler
EP2964801A4 (en) METAL-COATED STEEL STRIP
PL3387055T3 (pl) Sposób zmniejszania zamglenia z polipropylenu o wysokiej wytrzymałości stopu
HUE036116T2 (hu) Fémek kezelésére és olvasztására szolgáló eljárás és üzem
FR3045538B1 (fr) Moto-reducteur d&#39;essuie-glace
FR3037944B1 (fr) Materiau nanostructure de bore amorphe
EP3397071A4 (en) COMPOSITION FOR ENERGY SUPPLEMENT
DK3093053T3 (da) Klaringstank i ét stykke
GB2570610B (en) Improvements in or relating to area denial